纤维肌性发育不良市场（2026—2031）
纤维肌性发育不良市场规模预计由2026年的9亿美元增至2031年的12.3亿美元，预测期复合年增长率为6.33%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
纤维肌性发育不良市场规模预计由2026年的9亿美元增至2031年的12.3亿美元，预测期复合年增长率为6.33%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 6.33% | 机构预测 |
| 市场规模 | 2026 | USD 0.9 billion | 机构预测 |
| 市场规模 | 2031 | USD 1.23 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| age_group | geriatric patients | 2025 | 41.250% |
| component | treatment type | 2025 | 51.370% |
| end-user | hospitals | 2025 | 43.340% |
| geography | North America | 2025 | 47.160% |
关键结论
- age_group 维度中，geriatric patients 在 2025 年的公开份额为 41.25%。
- component 维度中，treatment type 在 2025 年的公开份额为 51.37%。
- end-user 维度中，hospitals 在 2025 年的公开份额为 43.34%。
- geography 维度中，North America 在 2025 年的公开份额为 47.16%。
主要参与者
- Abbott Laboratories
- Medtronic plc
- Boston Scientific Corporation
- Cook Medical LLC
- Terumo Corporation
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Recognition of FMD as a Systemic Arteriopathy | +1.200% | Global, with concentrated gains in North America and Europe | Medium term (2-4 years) |
| Adoption of CTA and MRA for Multivessel Screening | +1.500% | Global, with North America leading and Asia-Pacific accelerating | Short term (≤ 2 years) |
| Specialized Clinics and Multidisciplinary Care | +0.800% | North America and Europe, with early development in Asia-Pacific | Medium term (2-4 years) |
| Detection of Renovascular Hypertension in Younger Patients | +0.900% | Asia-Pacific, especially India and China, with spillover to the Middle East and Africa | Long term (≥ 4 years) |
| Use of Image-Guided Endovascular Intervention | +1.000% | North America and Europe, with Japan supporting Asia-Pacific adoption | Medium term (2-4 years) |
| Registry Evidence for Earlier Diagnosis and Follow-Up | +0.600% | North America and Europe, especially France, Belgium, and the United Kingdom | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Prolonged Diagnostic Delay and Underdiagnosis | -1.100% | Global, most acute in the Middle East and Africa and parts of Asia-Pacific | Long term (≥ 4 years) |
| Limited Randomized Evidence for FMD-Specific Therapies | -0.700% | Global, with pricing constraints in Europe and North America | Long term (≥ 4 years) |
| Small Diagnosed Patient Pool and Uncertain Disease Prevalence | -0.900% | Global | Long term (≥ 4 years) |
| Uneven Access to Expert Imaging and Interventional Care | -0.500% | Middle East and Africa, South America, and secondary Asia-Pacific markets | Medium term (2-4 years) |
报告关注的关键问题
What is the projected growth rate for fibromuscular dysplasia market through 2031?
The fibromuscular dysplasia market is projected to grow at a 6.33% CAGR from 2026 to 2031, rising from USD 0.85 billion in 2025 to USD 0.90 billion in 2026 to USD 1.23 billion in 2031.
Which FMD subtype has the largest revenue base?
Renal FMD held 39.61% of the disease-type segment in 2025 because it has an established diagnostic and interventional pathway.
Which component is growing fastest for FMD?
Diagnosis method is forecasted to grow at an 8.27% CAGR through 2031, driven by increasing use of advanced imaging techniques for early and accurate detection of fibromuscular dysplasia.
Which region is expected to grow fastest?
Asia-Pacific is projected to expand at an 8.24% CAGR through 2031 as hypertension detection, imaging access, and FMD awareness improve.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence